GamaMabs Pharma, a company incorporated in 2013, has licensed programs developed by LFB Biotechnologies.
With the objective of developing monoclonal antibodies for the treatment of cancer, GamaMabs Pharma owns the rights to a monoclonal antibody generation platform (Emabling®) and to a pipeline of several antibodies derived from this technology, the main one, 3C23K in pre-clinical phase, targeting AMHR2 in ovarian cancer.
Development of monoclonal antibodies for the treatment of cancer
Stéphane Degrove & Gérard Tiraby
IXO intervention: 1,05 M€
Sales figures: N.C.